Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

Denver TMAU Test Lab survey click here
click to Read more/less

USA survey for anyone who wants to improve Denver TMAU test

begun : Dec22
end : no ending for now

A trainee genetic counselor is working at the Denver TMAU test lab. Probably as part of her training. As a project she wishes feedback on any aspect of the Denver TMAU test and process. You can fill in the survey and/or email her (email address is in survey). It's meant for USA people, but perhaps others can give their view too (as we have so few opportunities).

quote from her rareconnect post

"Hello all! I wanted to make you aware of a research study being conducted to better understand the experience and needs of individuals with trimethylaminuria with a goal of being able to create improved patient and healthcare provider education materials. Any participation is completely voluntary and all responses remain confidential. Feel free to use the contact information within the link with any questions or share the survey with others with TMAU."

see this post for more details

Wednesday, October 9, 2013

Comment about the recent TMAU paper involving Professors Phillips and Shephard

We posted in the blog recently about a new research paper on trimethylaminuria in which Professors' Elizabeth Shephard and Ian Phillips were involved. They have kindly given us permission to post a quote about the paper.

The abstract of the paper can be read on pubmed : Relationships between flavin-containing monooxygenase 3 (FMO3) genotype and trimethylaminuria phenotype in a Japanese population

link : Pubmed TMAU paper abstract

Below is the quote given by Professors' Elizabeth Shephard and Ian Phillips about the paper 

Prof Phillips and Shephard : involved with this TMAU paper
1. Of the 13 individuals diagnosed as severe TMAurics are homozygous or compound heterozygous for mutations that severely affect FMO3 function. Given this preponderance of severe mutations, It is likely that the other 3 have unidentified mutations (in promoter or introns) that have a severe affect on expression or processing of FMO3.

2. Most of the TMAurics are classified (on the basis of urinary excretion) as moderate or mild TMAurics. Of these, none is homozygous or compound heterozygous for mutations that severely affect FMO3 activity. This suggests that it is unlikely that these phenotypes are a consequence of unidentified mutations that severely affect expression or activity of FMO3. However, it is possible that some of these individuals have unknown mutations that have moderate effects on expression of the gene or processing of the RNA.

3. Genotype-phenotype correlation: individuals homozygous or compound heterozygous for mutations that have a severe affect on FMO3 activity will suffer from severe TMAU. Therefore, severe TMAU can be diagnosed genetically. However, most TMAurics suffer from moderate or mild forms of the disorder; these cannot be diagnosed genetically and, thus, must be due to factors other than FMO3 genotype. It is likely that exon sequencing would identify only those affected by severe TMAU and, thus, would not be informative for the majority of TMAU sufferers.

4. For the group there is a strong correlation between total urinary TMA (TMA + TMA N-oxide) and the amount excreted as the free amine (TMA), which implies that individuals with moderate or mild TMAU would benefit from a reduction of total TMA load. 

A Public Charity
MEBO Research
MEBO's Blog (English)
El Blog de MEBO (español)
MEBO Brasil - Blog (Portuguese)

A EURORDIS and NORD Member Organization 


Post a Comment